Lifecore Biomedical (LFCR) Proxy filing summary

Executive summary

• Supplement updates the proxy statement for the August 15, 2024, annual meeting, specifically amending Proposal 7 regarding the increase in authorized shares and correcting typographical errors in the amendment language.

• The supplement clarifies the voting standard for Proposal 7 due to recent changes in Delaware law, affecting how votes, abstentions, and broker non-votes are counted.

• No other changes to the proxy statement or meeting matters are introduced by this supplement.

Voting matters and shareholder proposals

• Seven proposals will be voted on, including declassifying the board, electing directors, ratifying the auditor, executive compensation, amending the stock incentive plan, advisory vote on compensation frequency, and increasing authorized shares.

• Proposal 7 seeks to increase authorized common stock from 50,000,000 to 75,000,000 shares, requiring a majority of votes cast by both common and preferred stockholders, and separately by common stockholders.

• Abstentions and broker non-votes have no effect on Proposal 7; for other proposals, effects vary as detailed in the supplement.

Board of directors and corporate governance

• Election of three directors by all stockholders and one Series A Preferred Director by preferred stockholders is proposed.

• Board recommends voting "FOR" all director nominees and proposals.